Top

Published in:

01-03-2017 | Editorial

An introduction to CKD-MBD research: restart for the future

Authors: Masafumi Fukagawa, Masaaki Inaba, Keitaro Yokoyama, Takashi Shigematsu, Ryoichi Ando, Ken-ichi Miyamoto, For Japan CKD-MBD Forum

Published in: Clinical and Experimental Nephrology | Special Issue 1/2017

Excerpt

The kidney plays important roles in the regulation of mineral metabolism. It is not only the target organ of mineral regulating hormones, but also the main organ that activates vitamin D [1]. Accordingly, in CKD patients, various abnormalities develop in this system, such as secondary hyperparathyroidism [2, 3]. As partially depicted in this issue, Japanese researchers have substantially contributed to the elucidation of pathogenesis of these abnormalities, leading to the development of new therapeutic modalities [4‐6]. …

Fukagawa M, Hamada Y, Nakanishi S, Tanaka M. The kidney and bone metabolism: a nephrologist’s view. J Bone Mineral Metab. 2006;24:434–8.CrossRef

Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol. 2011;5:797–809.CrossRef

Komaba H, Kakuta T, Fukagawa M. Management of secondary hyperparathyroidism: how and why? Clin Exp Nephrol. 2017. doi:10.1007/s10157-016-1369-2.

Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T. Research on kidney and mineral metabolism in Japan: Past, present and future. Clin Exp Nephrol. 2017. doi:10.1007/s10157-016-1366-5.

Hamano T, Sakaguchi Y, Fujii N, Isaka Y. Clinical features of CKD-MBD in Japan: Cohort studies and registry. Clin Exp Nephrol. 2017. doi:10.1007/s10157-016-1367-4.

Miyamoto K-I, Kaneko I, Tatsumi S, Segawa H: Control of phosphate balance by the kidney and intestine. Clin Exp Nephrol. 2017. doi:10.1007/s10157-016-1359-4.

Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–53.CrossRefPubMed

Fuji H, Joki N. Mineral metabolism and cardiovascular disease in CKD. Clin Exp Nephrol. 2017. doi:10.1007/s10157-016-1363-8.

Komaba H, Fukagawa M. The role of FGF23 in CKD: with or without Klotho. Nature Review Nephrol. 2012;8:484–90.CrossRef

10.

Kuro-o M. The FGF23 and Klotho system beyond mineral metabolism. Clin Exp Nephrol. 2017. doi:10.1007/s10157-016-1357-6.

11.

Kazama JJ. Chronic kidney disease and fragilty fracture. Clin Exp Nephrol. 2017. doi:10.1007/s10157-016-1368-3.

12.

Goodkin DA, Bragg-Gresham JL, Koenig KC, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States. Dialysis Outcome Practice Patterns Study (DOPPS). 2003;14:3270–7.

13.

Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori M, Ashida A, Iseki K, Shigematsu T, Tsubakihara Y, Tomo T, Hirakata H. Akizawa T for CKD-MBD Guideline Working Group, Japanese Society for Dialysis Therapy: clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Ther Aphr Dial. 2013;17:247–88.CrossRef

14.

Taniguchi M, Fukagawa M, Fujii N, Hamano T, Shoji T, Yokoyama K, Nakai S, Shigematsu T, Iseki K, Tsubakihara Y. Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy: impact of mineral metabolism on mortality in hemodialysis patients: Serum phosphate level should be controlled firstly and consistently. Ther Aphr Dial. 2013;17:221–8.CrossRef

15.

Komaba H, Fukagawa M. Phosphate- a poison for humans? Kidney Int. 2016;90:753–63.CrossRefPubMed

16.

Taketani T, Koiwa F, Yokoyama K. Management of phosphorus load in CKD patients. Clin Exp Nephrol. 2017. doi:10.1007/s10157-016-1360-y.

17.

Tentori F, Wang M, Bieber B, Jacobson S, Andreucci V, Fukagawa M, Frimat L, Mendelssohn DA, Port F, Pisoni RL, Robinson BM. Secondary hyperparathyroidism among patients on chronic hemodialysis: recent changes in therapeutic approach and association with outcomes in the dialysis outcomes and practice pattern study (DOPPS). Clin J Am Soc Nephrol. 2015;10:98–109.CrossRefPubMed

18.

Hirukawa T, Kakuta T, Nakamura M, Fukagawa M. Mineral and bone disorders in kidney transplant recipients: reversible, irreversible and de novo abnormalities. Clin Exp Nephrol. 2015;19:543–55.CrossRefPubMed

19.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76(Supple 113):S1–S130.

20.

Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, Shroff R, Thadhani RI, Tonelli MA, Kasiske BL, Wheeler DC, Leonard MB. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: improving global outcomes controversies conference. Kidney Int. 2015;87:502–28.CrossRefPubMed

Title: An introduction to CKD-MBD research: restart for the future
Authors: Masafumi Fukagawa
Masaaki Inaba
Keitaro Yokoyama
Takashi Shigematsu
Ryoichi Ando
Ken-ichi Miyamoto
For Japan CKD-MBD Forum
Publication date: 01-03-2017
Publisher: Springer Japan
Published in: Clinical and Experimental Nephrology / Issue Special Issue 1/2017
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-016-1372-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

An introduction to CKD-MBD research: restart for the future

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2017

The FGF23 and Klotho system beyond mineral metabolism

Management of secondary hyperparathyroidism: how and why?

Chronic kidney disease and fragility fracture

Research on kidney and mineral metabolism in Japan: past, present, and future

Mineral metabolism and cardiovascular disease in CKD

Control of phosphate balance by the kidney and intestine

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page